11 Mar 2021 On March 10th 2021, Professor Owe Orwar, CEO presented Oblique Therapeutics AB at Carnegie Nordic Virtual Healthcare Seminar 2021.
08 Oct 2020 Oblique Therapeutics AB together with collaborators at Sahlgrenska University Hospital (Gothenburg) and Karolinska Institutet (Stockholm) has been granted 5MSEK by Vinnova to develop neutralizing antibodies towards SARS-CoV-2 and to develop its Abiprot platform into a first-line-of-defence for future pandemics.
21 Sep 2020 24th Sept 2020 – Oblique Therapeutics is delighted to be invited to speak at “Biopharma Conclave 2020”
14 Sep 2020 Oblique Therapeutics is honored to participate as speaker to the 2nd Edition RAS- Targeted Drug Development Congress 15th September 2020
29 Jun 2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms
11 Jun 2020 Oblique Therapeutics AB has identified a potentially important epitope for generation of SARS-CoV-2 antibodies
